August 23, 2021 7:47am
After a nerve-racking week of economic data and political/military shaming
News: Editas Medicine (EDIT announced data on a new gene editing technology termed SLEEK (SeLection by Essential-gene Exon Knock-in) enabling high knock-in efficiencies with different transgenes while also ensuring robust, transgene expression.
Pre-open indications: SELLs: 1; SELL into Strength: 4; Maintain SELL: 1
The Biostage Chronicles: Questions and more questions, the number increases without answers - transparency lacks!
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing!
What I provide is a trusted source of share pricing intelligence
Dow futures are UP +0.39% (+136 points), S&P futures are UP +0.32% (+14 point) and NASDAQ futures are also UP +0.30% (+46 points)
Stock futures were higher in Monday’s pre-open,
European markets were slightly higher,
Asia-Pacific markets advanced as most geographics followed Hong Kong’s Hang Seng index bounce-back
Data Docket: Traders are eagerly awaiting the Jackson Hole symposium for clues on the Fed’s timeline for dialing back its $120 billion a month bond-buying program. The event takes place virtually on Thursday and Friday.
Friday, cell and gene therapy stocks traded in the green, providing the sector with better support.
All three major stock indexes finished the week lower.
For the month of August, major; the S&P 500 is up +1.1%, the Dow gained +0.5% and the Nasdaq has climbed 0.3%.
If you didn’t know what happen at Friday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
- Friday’s evening’s recap: “a follow the bounce share pricing with low volume, negligible percentage (%) moves and volatility at least to the upside. What I have been saying the oversold would become buys” … https://www.regmedinvestors.com/articles/12060
- The Nasdaq closed UP +172.88 points (+1.19%)
- The IBB closed up +1.54% and XBI closed up +2.90%;
- Sector volume was LOW with 2 of the 26-upside having higher than the 3-month average volume with very LOW volume of 2 of 4-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -3.11 points or -14.35% at 18.56;
- Friday’s percentage (%) of the 26-upside were +0.37% (CRSP) to +6.58% (GBT) while the 5-downside -0.15% (MESO) to -21.74% (FATE);
- Q3/21: August: 7 positive and 8 negative close
- July: 6 positives, 1 holiday and 15 negative closes
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542 … to date:
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with and without being “pumped/promoted”?
Biostage (BSTG) closed down -$0.07 to $1.21 with 570 shares traded after Thursday’s flat with 50 shares traded, Wednesday’s -$0.10 with 739 shares traded, Tuesday’s flat with 1 share traded and last Monday’s -$0.22 to $1.38 with 135 shares traded.
Question#1: Protecting the share price is ONLY a temporary factor compared to the packing and inflated pricing of the private placements that jeopardizes ANY sort of future financing?
Question#2: With all the issues of transparency, is the biggest fear – being delisted?
Question#3: WHO is running this company? WHAT is the relationship with … LIU Dong-hai of Dixintong Technology Group in China of which Jason Chen is chairman of BSTG and a VP of Dixintong < whose parent company, D. Phone, is one of the largest smartphone retailers in China>. WHAT is LIU Dong-hai’s relationship with DST Capital in funding the company and managed by Mrs. bin Zhao of Weston, Ma? HOW many times did Shunfu Hu, VP of business development and operations say <to me> that Beijing, China based LIU Dong-hai was the ULTIMATE AUTHORITY in BSTG’s future?
Question#4: WHY does D. Phone, Dixintong Technology Group need a regenerative medicine/biotech public, debtor and money loosing company in its investment group that resides in the middle of scientific innovation in America?
Question#5: Is there another reason to funnel foreign national monies to this entity that has yet to initiate a clinical trial? The question is who is listening and reading the scientific access points?
Question#6: HOW did “this” all get started … is it related to get Chinese communist leaders and executive’s children into American schools and universities?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
Ionis Pharmaceuticals (IONS) closed up +$1.42 and has a negative -$0.21 or +0.53% (Friday) aftermarket indication,
SELL into Strength:
Cellectis SA (CLLS) closed up +$0.53 and has a positive +$0.30 or +2.41% pre-market indication,
Chinook Therapeutics (KDNY) closed up +$0.63 and has a positive +$0.47 or +3.68% (Friday) aftermarket indication,
Editas Medicine (EDIT) closed up +$2.28 and has a positive +$3.38 or +5.60% pre-market indication,
CRISPR Therapeutics (CTSP) closed up +0.43 and has a positive +1.77 or +1.51% pre-market indication,
The BOTTOM LINE: August is a historically volatile month for markets and this year is no different, with investors currently climbing multiple walls of worries …
The alternating cycle of being oversold is the ability to be overbought after multiple sessions.
When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started
Investors should take short-term profits to cash-up for coming drifts!
Some earnings’ Reports Outstanding:
- Applied Genetic Technologies (AGTC), Mesoblast (MESO), Pluristem (PSTI) and Pluristem (PSTI), ReNeuron (RENE.L)
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.